Bayer appoints Dr. Juergen Eckhardt as new Head of Pharmaceuticals Business Development & Licensing/Open Innovation
Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer
Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Subscribe To Our Newsletter & Stay Updated